Proteomic identification of serum biomarkers for head and neck cancer surveillance

Laryngoscope

Volumn 119, Issue 7, 2009, Pages 1291-1302

  Gourin, Christine G ^a   Zhi, Wenbo ^b   Adam, Bao Ling ^b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Head and neck neoplasms; Proteomics; Recurrence; Serum; Squamous cell cancer

Indexed keywords

ANGIOTENSINOGEN; ANTIOXIDANT; APOLIPOPROTEIN A1; BIOLOGICAL MARKER; CYSTEINE PROTEINASE INHIBITOR; CYTOKERATIN 2; KININOGEN; PLASMA PROTEIN; PROAPOLIPOPROTEIN; SERINE PROTEINASE; SERINE PROTEINASE INHIBITOR; THIOL SPECIFIC ANTIOXIDANT; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; DISEASE CLASSIFICATION; FEMALE; HEAD AND NECK CANCER; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS;

ADOLESCENT; ADULT; AGED; CARCINOMA, SQUAMOUS CELL; CHI-SQUARE DISTRIBUTION; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; PROTEOMICS; REGRESSION ANALYSIS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; STATISTICS, NONPARAMETRIC; TUMOR MARKERS, BIOLOGICAL;

EID: 67949103390     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1002/lary.20279     Document Type: Article

References (34)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Thun MJ. Cancer statistics. CA Cancer J Clin 2007; 57:43-66.
2. Gleich LL, Salamone FN. Molecular genetics of head and neck cancer. Cancer Control 2002; 9:369-378.
3. Gleich LL, Li YQ, Wang X., Stambrook PJ, Gluckman JL. Variable genetic alterations and survival in head and neck cancer. Arch Otolaryngol Head Neck Surg 1999; 125: 949-952.
4. Wiseman SM, Stoler DL, Anderson GR. The role of genomic instability in the pathogenesis of squamous cell carcinoma of the head and neck. Surg Oncol Clin N Am 2004; 13:1-11.
5. Yarbrough WG, Slebos RJ, Leibler D. Proteomics: clinical applications for head and neck squamous cell carcinoma. Head Neck 2006; 28:549-558.
6. Spisak S., Tulassay Z., Molnar B., Guttman A. Protein microchips in biomedicine and biomarker discovery. Electrophoresis 2007; 28:4261-4273.
7. Soltys SG, Le QT, Shi G., Tibshirani R., Giaccia AJ, Koong AC. The use of plasma surface-enhanced laser desorption/ionization time-of-flight mass spectrometry proteomic patterns for detection of head and neck squamous cell cancers. Clin Cancer Res 2004; 10:4806-4812.
8. Wadsworth JT, Somers KD, Stack BC Jr, et al. Identification of patients with head and neck cancer using serum protein profiles. Arch Otolaryngol Head Neck Surg 2004; 130:98-104.
9. Gourin CG, Xia ZS, Han T., et al. Serum protein profile analysis in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2006; 132: 390-397.
10. Gourin CG, Moretz WH III, Weinberger PM, et al. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 2007; 133:1125-1130.
11. Freed GL, Cazares LH, Fichandler CE, et al. Differential capture of serum proteins for expression profiling and biomarker discovery in pre-and posttreatment head and neck cancer samples. Laryngoscope 2008; 118:61-68.
12. Adam BL, Qu Y., Davis JW, et al. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 2002; 62:3609-3614.
13. Kohavi R. A. study of cross-validation and bootstrap for accuracy estimation and model selection. In: Wermter S., Riloff E., Scheler G., eds. The Fourteenth International Joint Conference on Artificial Intelligence (IJCAI). San Francisco, CA: Morgan Kaufman; 1995:1137-1145.
14. Zhou G., Li H., Gong Y., et al. Proteomic analysis of global alteration of protein expression in squamous cell carcinoma of the esophagus. Proteomics 2005; 5:3814-3821.
15. Badola S., Spurling H., Robison K., et al. Correlation of serpin-protease expression by comparative analysis of realtime PCR profiling data. Genomics 2006; 88:173-184.
16. Liang X., Huuskonen J., Hajivandi M., et al. Identification and quantification of proteins differentially secreted by a pair of normal and malignant breast-cancer cell lines. Proteomics 2009; 9:182-193.
17. O-Charoenrat P., Rusch V., Talbot SG, et al. Casein kinase II alpha subunit and C1-inhibitor are independent predictors of outcome in patients with squamous cell carcinoma of the lung. Clin Cancer Res 2004; 10:5792-5803.
18. Gonzalez-Zuloeta Ladd AM, Arias Vasquez A., Siemes C., et al. Differential roles of Angiotensinogen and Angiotensin Receptor type 1 polymorphisms in breast cancer risk. Breast Cancer Res Treat 2007; 10:299-304.
19. Bouquet C., Lamande N., Brand M., et al. Suppression of angiogenesis, tumor growth, and metastasis by adenovirus-mediated gene transfer of human angiotensinogen. Mol Ther 2006; 14:175-182.
20. Sugimoto M., Furuta T., Shirai N., et al. Role of angiotensinogen gene polymorphism on Helicobacter pylori infectionrelated gastric cancer risk in Japanese. Carcinogenesis 2007; 28:2036-2040.
21. Bior AD, Pixley RA, Colman RW Domain 5 of kininogen inhibits proliferation of human colon cancer cell line (HCT-116) by interfering with Gl/S in the cell cycle. J Thromb Haemost 2007; 5:403-411.
22. Daly ME, Makris A., Reed M., Lewis CE. Hemostatic regulators of tumor angiogenesis: a source of antiangiogenic agents for cancer treatment? J Natl Cancer Inst 2003; 95: 1660-1673.
23. Kawasaki M., Maeda T., Hanasawa K., Ohkubo I., Tani T. Effect of His-Gly-Lys motif derived from domain 5 of high molecular weight kininogen on suppression of cancer metastasis both in vitro and in vivo. J Biol Chem 2003; 278: 49301-49307
24. Abdul-Rahman PS, Lim BK, Hashim OH. Expression of high-abundance proteins in sera of patients with endometrial and cervical cancers: analysis using 2-DE with silver staining and lectin detection methods. Electrophoresis 2007; 28:1989-1996.
25. Borgono CA, Michael IP, Shaw JL, et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 2007; 282:2405-2422.
26. Collin C., Moll R., Kubicka S., Ouhayoun JP, Franke WW. Characterization of human cytokeratin 2, an epidermal cytoskeletal protein synthesized late during differentiation. Exp Cell Res 1992; 202:132-141.
27. Collin C., Ouhayoun JP, Grund C., Franke WW. Suprabasal marker proteins distinguishing keratinizing squamous epithelia: cytokeratin 2 polypeptides of oral masticatory epithelium and epidermis are different. Differentiation 1992; 5:137-148.
28. Park SH, Chung YM, Lee YS, et al. Antisense of human peroxiredoxin II enhances radiation-induced cell death. Clin Cancer Res 2000; 6:4915-4920.
29. Wang T., Tamae D., LeBon T., et al. The role of peroxiredoxin II in radiation-resistant MCF-7 breast cancer cells. Cancer Res 2005; 65:10338-10346.
30. Huang HL, Stasyk T., Morandell S., et al. Biomarker discovery in breast cancer serum using 2-D differential gel electrophoresis/MALDI-TOF/TOF and data validation by routine clinical assays. Electrophoresis 2006; 27:1641-1650.
31. Nossov V., Amneus M., Su F., et al. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125? Am J Obstet Gynecol 2008; 199:215-223.
32. Hortin GL. The MALDI-TOF mass spectrometric view of the plasma proteome and peptidome. Clin Chem 2006; 52: 1223-1227.
33. Marchi N., Mazzone P., Fazio V., et al. Proapolipoprotein A1. A serum marker of brain metastases in lung cancer patients. Cancer 2008; 112:1313-1324.
34. McLerran D., Grizzle WE, Feng Z., et al. SELDI-TOF MS whole serum proteomic profiling with IMAC surface does not reliably detect prostate cancer. Clin Chem 2008; 54: 53-60.